The dream of a completely closed-loop system for diabetes management is now closer than ever for many Type 1 diabetes patients, thanks to the widespread U.S. launch of a completely automated, ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...

Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further. When the FDA originally cleared the automated, ...

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation's Omnipod 5 Automated Insulin Delivery System ...

Mass.-based insulin-pump maker Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for $25 million. Insulet and Bigfoot offer two distinct ...

As a child with Type 1 diabetes, Arden Benner of Robbinsville, New Jersey, has gotten used to needle sticks and injections. Scott Benner, her father, says, "21 injections every 3 days, plus her finger ...

Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...

First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic ...